Conditions: Delayed Graft Function
Keywords: DGF Dialysis Kidney Kidney Transplantation eGFR Complement Eculizumab
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 288
Healthy volunteers: no

Brief summary:
The purpose of this study was to determine if eculizumab is safe and could be used to prevent delayed graft function (DGF) following kidney transplantation.

Detailed description:

Arms:
arm 1: Eculizumab was administered by intravenous (IV) infusion over 25-45 minutes (min) for 2 doses (on the day of transplant then 18-24 hours \[h\] later). arm 2: Placebo was administered by IV infusion over 25-45 min for 2 doses (on the day of transplant then 18-24 h later).

Interventions: intervention 1: Eculizumab intervention 2: Placebo
Intervention descriptions: intervention 1: Eculizumab is a complement component 5 inhibitor. intervention 2: 0.9% sodium chloride

Protocol document: